In the SURMOUT-1 trial 2,539 patients underwent randomization to tirzepatide or placebo and were followed for 72 weeks demonstrating up to 20.9% weight reduction with maintenance dosing versus 3.1% in the placebo group for a net 17.8% weight reduction [35]
Different GLP-1 receptor agonists have distinct administration requirements, and following the correct instructions is essential for optimal therapeutic benefit
If the scheduled date was more than 5 days ago, skip the dose and take the next scheduled dose according to your treatment plan
You pay a premium per milligram for the convenience of a smaller commitment
An employer can offer 50% coinsurance, contribute a nominal amount, or anything in between
doi:10.1056/NEJMoa2301972 PubMed: This landmark study demonstrated 24.2% mean weight loss at 48 weeks with the 12mg dose in 338 adults with obesity, establishing retatrutide as the most effective obesity medication tested to date